The US FDA has approved a combination of pembrolizumab and berahyaluronidase injection for the treatment of 18 cancers, including melanoma, lung, gastric, urothelial, and breast cancers. Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa is an endoglycosidase.
##Indication## Melanoma Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Head and Neck Squamous Cell Cancer Urothelial Cancer Microsatellite Instability-High or Mismatch Repair Deficient Cancer Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer Gastric Cancer Esophageal Cancer Cervical Cancer Hepatocellular Carcinoma Biliary Tract Cancer Merkel Cell Carcinoma Renal Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer## Clinical evidence In clinical trials…
